Atara closes on first approval of transplant complication th...

Atara Biotherapeutics' cell therapy Ebvallo should be approved to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), according to the EMA's human med

Milestone as EMA starts review of Atara's 'off-the-shelf' ce...

Atara Biotherapeutics' tabelecleucel (tab-cel) has become the first 'allogeneic' cell therapy – in other words one which doesn't involve harvesting cells from patients – to be evaluated by

NICE says yes to Braftovi combination for colorectal cancer

Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has changed its mind, and now says the drug can be funded by the NHS in Engla

Array, Pierre Fabre bowel cancer therapy ‘could replace chem...

Pierre Fabre to launch blockchain patient engagement pilot

Pierre Fabre Pharmaceuticals has joined a blockchain consortium that allows patients to share real-time digital health data to inform late-stage clinical research.